Karyopharm Therapeutics Inc. (KPTI) saw its loss widen to $29.92 million, or $0.71 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $27.06 million, or $0.75 a share. Revenues for the quarter were $0.07 million. The company has not recorded any revenues for the previous year period.
Operating loss for the quarter was $30.28 million, compared with an operating loss of $27.35 million in the previous year period.
"It’s been a highly active early 2017 for Karyopharm, marked most notably by establishment of a planned approval path for selinexor in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), our second lead indication after multiple myeloma (MM), following the presentation of robust interim data from the Phase 2b SADAL study at the American Association for Cancer Research (AACR) 2017 Annual Meeting," said Michael G. Kauffman, MD, PhD, chief executive officer of Karyopharm.
Working capital declines
Karyopharm Therapeutics Inc. has witnessed a decline in the working capital over the last year. It stood at $96.75 million as at Mar. 31, 2017, down 22.55 percent or $28.17 million from $124.92 million on Mar. 31, 2016. Current ratio was at 7.25 as on Mar. 31, 2017, down from 10.45 on Mar. 31, 2016.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: editor@irisindia.net
